Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | See Remarks | March 01, 2017 | March 01, 2017 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Chief Operating Officer | July 15, 2025 | July 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Matinas BioPharma Holdings, Inc.
Report date March 01, 2017 · Filed March 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2017-03-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 80,000 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.52 · Expires 2025-03-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The option award was made in accordance with the terms of the issuer's Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on March 12, 2015. The exercise price is based on the average of the closing bid and asked prices for the shares of the Common Stock on the OTC.QB on the date of grant in accordance with the terms of the 2013 Plan. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2026-02-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The option award was made in accordance with the terms of the issuer's Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan. The option vests in equal monthly installments over a period of 36 months commencing on February 15, 2016. The exercise price is based on the average of the closing bid and asked prices for the shares of the Common Stock on the OTC.QB on the date of grant in accordance with the terms of the 2013 Plan. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.32 · Expires 2027-02-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-03-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: The option award was made in accordance with the terms of the issuer's Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan. The option vests in equal monthly installments over a period of 36 months commencing on February 21, 2017. The exercise price is based on the average of the closing bid and asked prices for the shares of the Common Stock on the OTC.QB on the date of grant in accordance with the terms of the 2013 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the issuer's Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on March 12, 2015. The exercise price is based on the average of the closing bid and asked prices for the shares of the Common Stock on the OTC.QB on the date of grant in accordance with the terms of the 2013 Plan.
F2: The option award was made in accordance with the terms of the issuer's Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan. The option vests in equal monthly installments over a period of 36 months commencing on February 15, 2016. The exercise price is based on the average of the closing bid and asked prices for the shares of the Common Stock on the OTC.QB on the date of grant in accordance with the terms of the 2013 Plan.
F3: The option award was made in accordance with the terms of the issuer's Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan. The option vests in equal monthly installments over a period of 36 months commencing on February 21, 2017. The exercise price is based on the average of the closing bid and asked prices for the shares of the Common Stock on the OTC.QB on the date of grant in accordance with the terms of the 2013 Plan.
NewAmsterdam Pharma Co N.V.
Report date July 15, 2025 · Filed July 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 44,000 |
Ending reported balance
After 2025-07-16 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2025-07-15 · Exercise / conversion · Acquired 47,569 · Balance 91,569 Row 2 · 2025-07-15 · Sale · Disposed 44,025 · Balance 47,544 F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.02 per share to $22.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Row 3 · 2025-07-15 · Sale · Disposed 3,544 · Balance 44,000 F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.02 per share to $22.22 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Row 4 · 2025-07-16 · Exercise / conversion · Acquired 51,043 · Balance 95,043 Row 5 · 2025-07-16 · Sale · Disposed 51,043 · Balance 44,000 F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.88 per share to $21.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2033-01-01 | Direct | 213,745 |
Reported balance
After 2025-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-07-15 · Exercise / conversion · Disposed 47,569 · Balance 213,745 F5: The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2033-01-01 | Direct | 162,702 |
Reported balance
After 2025-07-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-07-16 · Exercise / conversion · Disposed 51,043 · Balance 162,702 F5: The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.02 per share to $22.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.02 per share to $22.22 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.88 per share to $21.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F5: The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2025 Filed Jul 17, 2025 21:19 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 51,043 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0000950170-25-096665 · ownership.xml · derivative · entry 7 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,702 Underlying: Ordinary Shares · 51,043 shares Expires 2033-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| July 16, 2025 Filed Jul 17, 2025 21:19 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 51,043 | $21.10 | $1,077,007.30 |
DisclosureSEC source: 0000950170-25-096665 · ownership.xml · nonDerivative · entry 5 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.88 per share to $21.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| July 16, 2025 Filed Jul 17, 2025 21:19 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 51,043 | $10.90 | $556,368.70 |
DisclosureSEC source: 0000950170-25-096665 · ownership.xml · nonDerivative · entry 4 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:19 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 47,569 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0000950170-25-096665 · ownership.xml · derivative · entry 6 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,745 Underlying: Ordinary Shares · 47,569 shares Expires 2033-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:19 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 3,544 | $22.12 | $78,393.28 |
DisclosureSEC source: 0000950170-25-096665 · ownership.xml · nonDerivative · entry 3 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.02 per share to $22.22 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:19 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 44,025 | $21.38 | $941,254.50 |
DisclosureSEC source: 0000950170-25-096665 · ownership.xml · nonDerivative · entry 2 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,544 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.02 per share to $22.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:19 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 47,569 | $10.90 | $518,502.10 |
DisclosureSEC source: 0000950170-25-096665 · ownership.xml · nonDerivative · entry 1 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:50 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 21,899 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0000950170-25-087937 · ownership.xml · derivative · entry 6 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 261,314 Underlying: Ordinary Shares · 21,899 shares Expires 2033-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:50 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 78,101 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087937 · ownership.xml · derivative · entry 5 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 372,829 Underlying: Ordinary Shares · 78,101 shares Expires 2032-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:50 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 18,109 | $19.75 | $357,652.75 |
DisclosureSEC source: 0000950170-25-087937 · ownership.xml · nonDerivative · entry 4 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.60 per share to $20.21 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:50 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 81,891 | $19.19 | $1,571,488.29 |
DisclosureSEC source: 0000950170-25-087937 · ownership.xml · nonDerivative · entry 3 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,109 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.60 per share to $19.59 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:50 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 21,899 | $10.90 | $238,699.10 |
DisclosureSEC source: 0000950170-25-087937 · ownership.xml · nonDerivative · entry 2 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:50 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 78,101 | $10.00 | $781,010.00 |
DisclosureSEC source: 0000950170-25-087937 · ownership.xml · nonDerivative · entry 1 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:44 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074463 · ownership.xml · derivative · entry 3 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 450,930 Underlying: Ordinary Shares · 100,000 shares Expires 2032-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:44 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074463 · ownership.xml · nonDerivative · entry 2 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: These shares were sold in multiple transactions at prices ranging from $18.38 per share to $18.89 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:44 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 100,000 | $10.00 | $1,000,000.00 |
DisclosureSEC source: 0000950170-25-074463 · ownership.xml · nonDerivative · entry 1 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 21:41 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000950170-25-055612 · ownership.xml · derivative · entry 4 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 550,930 Underlying: Ordinary Shares · 100,000 shares Expires 2032-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 21:41 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 910 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-055612 · ownership.xml · nonDerivative · entry 3 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: These shares were sold in multiple transactions at prices ranging from $16.70 per share to $16.88 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 21:41 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 99,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-055612 · ownership.xml · nonDerivative · entry 2 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,910 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: These shares were sold in multiple transactions at prices ranging from $15.70 per share to $16.65 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 21:41 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 100,000 | $10.00 | $1,000,000.00 |
DisclosureSEC source: 0000950170-25-055612 · ownership.xml · nonDerivative · entry 1 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:18 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionRestricted Stock Unit · Derivative | 16,539 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-046943 · ownership.xml · derivative · entry 4 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 16,539 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share. F4 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. F3 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested. F3 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:18 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantRestricted Stock Unit · Derivative | 16,539 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-046943 · ownership.xml · derivative · entry 3 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,539 Underlying: Ordinary Shares · 16,539 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share. F4 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. F3 · derivative.exercise_date: Upon grant, all of the RSUs were fully-vested. F3 · derivative.expiration_date: Upon grant, all of the RSUs were fully-vested. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:18 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 16,539 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-046943 · ownership.xml · nonDerivative · entry 2 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 F1 · price: These shares were sold in multiple transactions at a price ranging from $22.75 to $23.20 per share. A portion of the ordinary shares were sold to satisfy tax withholding obligations arising upon the vesting of the restricted stock units ("RSUs"). The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Comission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 21:18 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 16,539 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-046943 · ownership.xml · nonDerivative · entry 1 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:29 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 11,888 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000950170-25-042176 · ownership.xml · derivative · entry 5 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 650,930 Underlying: Ordinary Shares · 11,888 shares Expires 2032-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:29 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 88,112 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-042176 · ownership.xml · derivative · entry 4 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,251 Underlying: Ordinary Shares · 88,112 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of the option is 1.16392 euros. F4 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:29 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-042176 · ownership.xml · nonDerivative · entry 3 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: These shares were sold in multiple transactions at prices ranging from $23.16 per share to $23.66 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:29 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 11,888 | $10.00 | $118,880.00 |
DisclosureSEC source: 0000950170-25-042176 · ownership.xml · nonDerivative · entry 2 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:29 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 88,112 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-042176 · ownership.xml · nonDerivative · entry 1 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The exercise price of the option is 1.16392 euros. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 9,218 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024322 · ownership.xml · derivative · entry 6 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,145 Underlying: Ordinary Shares · 9,218 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 9,218 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-024322 · ownership.xml · nonDerivative · entry 4 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: These shares were sold in multiple transactions at prices ranging from $19.23 per share to $20.18 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 9,218 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-024322 · ownership.xml · nonDerivative · entry 3 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The exercise price of the option is 1.16392 euros. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 90,782 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024322 · ownership.xml · derivative · entry 5 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,363 Underlying: Ordinary Shares · 90,782 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of the option is 1.16392 euros. F5 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 90,782 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-024322 · ownership.xml · nonDerivative · entry 2 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: These shares were sold in multiple transactions at prices ranging from $19.54 per share to $20.38 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 90,782 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-024322 · ownership.xml · nonDerivative · entry 1 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The exercise price of the option is 1.16392 euros. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 22:00 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 13,578 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-011854 · ownership.xml · derivative · entry 7 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 226,145 Underlying: Ordinary Shares · 13,578 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of the option is 1.16392 euros. F6 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 22:00 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 8,914 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-011854 · ownership.xml · nonDerivative · entry 5 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: These shares were sold in multiple transactions at prices ranging from $21.33 per share to $21.93 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 22:00 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 4,664 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-011854 · ownership.xml · nonDerivative · entry 4 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,914 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: These shares were sold in multiple transactions at prices ranging from $20.33 per share to $21.32 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 22:00 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 13,578 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-011854 · ownership.xml · nonDerivative · entry 3 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The exercise price of the option is 1.16392 euros. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 22:00 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 56,863 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-011854 · ownership.xml · derivative · entry 6 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,723 Underlying: Ordinary Shares · 56,863 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of the option is 1.16392 euros. F6 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 22:00 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 56,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-011854 · ownership.xml · nonDerivative · entry 2 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: These shares were sold in multiple transactions at prices ranging from $20.60 per share to $21.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 22:00 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 56,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-011854 · ownership.xml · nonDerivative · entry 1 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The exercise price of the option is 1.16392 euros. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:16 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 25,385 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-010575 · ownership.xml · derivative · entry 8 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,586 Underlying: Ordinary Shares · 25,385 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of the option is 1.16392 euros. F7 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:16 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 5,148 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-010575 · ownership.xml · nonDerivative · entry 6 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: These shares were sold in multiple transactions at prices ranging from $21.93 per share to $22.39 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:16 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 20,237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-010575 · ownership.xml · nonDerivative · entry 5 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,148 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: These shares were sold in multiple transactions at prices ranging from $20.92 per share to $21.91 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:16 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 25,385 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-010575 · ownership.xml · nonDerivative · entry 4 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The exercise price of the option is 1.16392 euros. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:16 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 104,174 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-010575 · ownership.xml · derivative · entry 7 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 321,971 Underlying: Ordinary Shares · 104,174 shares Expires 2031-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price of the option is 1.16392 euros. F7 · derivative.exercise_date: The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:16 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 23,815 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-010575 · ownership.xml · nonDerivative · entry 3 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: These shares were sold in multiple transactions at prices ranging from $23.46 per share to $23.70 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:16 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 80,359 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-010575 · ownership.xml · nonDerivative · entry 2 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,815 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: These shares were sold in multiple transactions at prices ranging from $22.46 per share to $23.45 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:16 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 104,174 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-010575 · ownership.xml · nonDerivative · entry 1 Kling Douglas F · CIK 0001699022 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The exercise price of the option is 1.16392 euros. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.